Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 2, 2014, Pages 337-343

  Matsushita, Hiroshi ^a   Ikeda, Fusao ^a,b   Iwasaki, Yoshiaki ^c   Seki, Hiroyuki ^a   Nanba, Shintaro ^a   Takeuchi, Yasuto ^a   Moritou, Yuki ^a   Yasunaka, Tetsuya ^a   Onishi, Hideki ^a,b   Miyake, Yasuhiro ^a   Takaki, Akinobu ^a   Nouso, Kazuhiro ^a,b   Yamamoto, Kazuhide ^a,b  

^a Department of Gastroenterology and Hepatology ^*  (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

HCV; Interferon; QOL

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERFERON; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHORT FORM 36; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; CLASSIFICATION; DRUG COMBINATION; FORECASTING; GENETICS; HCV; HEALTH SURVEY; HEPATITIS C VIRUS; METHODOLOGY; PSYCHOLOGICAL ASPECT; QOL; QUALITY OF LIFE; SEROTYPING; STATISTICAL MODEL; VIROLOGY;

HCV; INTERFERON; QOL;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FORECASTING; HEALTH SURVEYS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOMBINANT PROTEINS; RIBAVIRIN; SEROTYPING; TREATMENT OUTCOME;

EID: 84907290716     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12337     Document Type: Article

References (24)

1. Kato N. Molecular virology of hepatitis C virus. Acta Med. Okayama 2001; 55: 133-159.
2. Thomas DL. Hepatitis C epidemiology. Curr. Top. Microbiol. Immunol. 2000; 242: 25-41.
3. Firpi RJ, Nelson DR. Current and future hepatitis C therapies. Arch. Med. Res. 2007; 38: 678-690.
4. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
5. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
6. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J. Hepatol. 2012; 56: 78-84.
7. Zuluaga MC, Guallar-Castillon P, Lopez-Garcia E etal. Generic and disease-specific quality of life as a predictor of long-term mortality in heart failure. Eur. J. Heart Fail. 2010; 12: 1372-1378.
8. Pihl E, Jacobsson A, Fridlund B, Stromberg A, Martensson J. Depression and health-related quality of life in elderly patients suffering from heart failure and their spouses: a comparative study. Eur. J. Heart Fail. 2005; 7: 583-589.
9. Spiegel B, Harris L, Lucak S etal. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am. J. Gastroenterol. 2009; 104: 1984-1991.
10. Landman GW, van Hateren KJ, Kleefstra N, Groenier KH, Gans RO, Bilo HJ. Health-related quality of life and mortality in a general and elderly population of patients with type 2 diabetes (ZODIAC-18). Diabetes Care 2010; 33: 2378-2382.
11. Winter Y, Epifanova-Bertschi N, Sankowski R etal. Health-related quality of life and its determinants in the urban Russian population with major depressive disorder: a cross-sectional study. Int. J. Psychiatry Med. 2012; 43: 35-49.
12. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-212.
13. Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ. Treatment of cytokine-induced depression. Brain Behav. Immun. 2002; 16: 575-580.
14. Quarantini LC, Miranda-Scippa A, Batista-Neves S etal. The effect of early virological response in health-related quality of life in HCV-infected patients. J. Med. Virol. 2008; 80: 419-423.
15. Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R. Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-alpha and ribavirin therapy: a prospective evaluation. Am. J. Gastroenterol. 2011; 106: 2123-2132.
16. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.
17. Myers RP, Cooper C, Sherman M etal. Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Can. J. Gastroenterol. 2011; 25: 503-510.
18. Taliani G, Rucci P, Biliotti E etal. Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. J. Viral Hepat. 2007; 14: 875-882.
19. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J. Hepatol. 2012; 57: 946-952.
20. Raison CL, Broadwell SD, Borisov AS etal. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav. Immun. 2005; 19: 23-27.
21. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J. Clin. Epidemiol. 1998; 51: 1037-1044.
22. Fukuhara S, Ware JE, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 health survey. J. Clin. Epidemiol. 1998; 51: 1045-1053.
23. Suzukamo Y, Fukuhara S, Green J, Kosinski M, Gandek B, Ware JE. Validation testing of a three-component model of Short Form-36 scores. J. Clin. Epidemiol. 2011; 64: 301-308.
24. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.